eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
6/2010
vol. 5
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy and safety of pegylated interferon α-2b and ribavirin in chronic hepatitis C in children

Joanna Kupś-Rzepecka
,
Violetta Gołąbek
,
Przemysław Kiciński
,
Teresa Woźniakowska-Gęsicka

Przegląd Gastroenterologiczny 2010; 5 (6): 341–348
Online publish date: 2010/12/08
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction : Encouraging results of combined therapy in the treatment of chronic HCV infection in adults became a premise to apply such treatment in children. The correctness of this decision is reinforced by the fact that in children there were observed most of the factors which forecast obtaining a sustained viral response (SVR), such as: shorter duration of HCV infection, lower grade fibrosis and less severe side effects related to the applied medications.

Aim : To assess the efficacy and safety of peginterferon -2b therapy of chronic hepatitis C in children.

Material and methods : The study comprised 32 children (25 boys and 7 girls,) aged between 12 and 18 years, with chronic hepatitis C treated with peginterferon -2b and ribavirin. Half of these children had previously been treated with recombined interferon -2b and ribavirin to no effect. The treatment included peginterferon -2b (PegIntron) administered subcutaneously 1.5 µg/kg once per week and ribavirin orally 15 mg/kg/day for a period of 12 months. SVR was estimated after 6 months from the end of therapy.

Results : A sustained viral response was observed in 13 (40.6%) of 32 treated children. In 16 children who had previously been treated with recombined interferon a-2b and ribavirin a sustained viral response was documented in 3 (18.8%) of them. However, in children treated for the first time, SVR was achieved in 62.5%.

Conclusions : Peginterferon and ribavirin should be applied in children with chronic hepatitis C as a first-line therapy, guaranteeing higher effectiveness than the earlier applied pattern of treatment. Peginterferon therapy is safe and well tolerated by the children.
keywords:

hepatitis C, treatment, pegylated interferon -2b, children

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe